Xavier DuportetMEng, MSc, PhD
Xavier Duportet cofounded Eligo Bioscience in 2014, while doing his PhD in Synthetic Biology at MIT and INRIA. After being recognized as a Technology Pioneer in 2017 by the World Economic Forum, Eligo raised $24M from Khosla Ventures and Seventure to speed up the development of a new generation of ultra-precise biotherapeutics to battle antibiotic-resistant bacteria and sculpt our microbiome using genetic engineering and CRISPR/Cas. Xavier Duportet is an MIT TR35 and was elected French Innovator of the year by the MIT Technology Review in 2015. He has recently been of the 40 under 40 Young Leaders in Europe, one of the 30 Under 30 by Forbes in 2017 and a Young Global Leader by the WEF in 2018.